Bispecific-armed, interferon γ-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma

Blood

Volumn 87, Issue 9, 1996, Pages 3813-3821

  Ely, Pamela ^a   Wallace, Paul K ^b   Givan, Alice L ^b   Graziano, Robert F ^b   Guyre, Paul M ^b   Fanger, Michael W ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; GAMMA INTERFERON;

ANTIGEN BINDING; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MACROPHAGE; NONHODGKIN LYMPHOMA; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 0030005647     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.9.3813.bloodjournal8793813     Document Type: Article

References (42)

1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CAJ, Miller TP: A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 5:91, 1994 (suppl)
2. Kessinger A, Nademanee A, Forman SJ, Armitage JO: Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 4:577, 1990
3. Vuist WM, Levy R, Maloney DG: Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 83:899, 1994
4. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73:651, 1989
5. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863, 1992
6. Dyer MJ, Hale G, Hayhoe FG, Waldmann H: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73:1431, 1989
7. Hekman A, Honselaar A, Vuist WM, Sein JJ, Rodenhuis S, ten Bokkel Huinink WW, Somers R, Rumke P, Melief CJ: Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 32:364, 1991
8. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457, 1994
9. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V: A phase I study of an anti-CD22-deglycosylated nein A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624, 1993
10. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blattler WA, Epstein CL: Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 81:2263, 1993
11. Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blattler WA, Epstein CL: Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11:726, 1993
12. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052, 1991
13. Bonardi MA, Bell A, French RR, Gromo G, Hamblin T, Modena D, Tutt AL, Glennie MJ: Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. Int J Cancer 7:73, 1992 (suppl)
14. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459, 1993
15. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA: Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7:1027, 1989
16. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219, 1993
17. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E, Liu CP: Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10:1696, 1992
18. Glennie MJ, McBride HM, Worth AT, Stevenson GT: Preparation and performance of bispecific F(ab′ gamma)2 antibody containing thioether-linked Fab′ gamma fragments. J Immunol 139:2367, 1987
19. Wallace PK, Howell AL, Fanger MW: Role of Fc gamma receptors in cancer and infectious disease. J Leukoc Biol 55:816, 1994
20. Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-Ma ST, Ring DB, Alpaugh RK: Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol 151:2877, 1993
21. Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VRJ, Segal DM, Wunderlich JR: Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab′)2 antibody prolong host survival in a murine xenograft model. Cancer Res 51:5716, 1991
22. Fanger MW, Shen L, Graziano RF, Guyre PM: Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 10:92, 1989
23. van de Winkel JGJ, Capel PJ: Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications. Immunol Today 14:215, 1993
24. Valone FH, Kaufman PA, Guyre PM, Lewis L, Memoli V, Deo Y, Graziano RF, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre VC, Morley TL, Arvizu C, Fanger MW: Phase Ia/Ib trial of bispecific antibody MDX210 (anti-HER-2/neu X anti-Fc gamma RI) in patients with advanced breast or ovarian cancer that over-expresses the proto-oncogene HER-2/neu. J Clin Oncol 13:2281, 1995
25. Valerius T, Repp R, de Wit TP, Berthold S, Platzer E, Kalden JR, Gramatzki M, van de Winkel JGJ: Involvement of the high-affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 82:931, 1993
26. Anderson CL, Guyre PM, Whitin JC, Ryan DH, Looney RJ, Fanger MW: Monoclonal antibodies to Fc receptors for IgG on human mononuclear phagocytes: Antibody characterization and induction of superoxide production in a monocyte cell line. J Biol Chem 261:12856, 1986
27. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW: Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J Immunol 143:1650, 1989
28. Mentzer SJ, Guyre PM, Burakoff SJ, Faller DV: Spontaneous aggregration as a mechanism for human monocyte purifcation. Cell Immunol 101:312, 1986
29. Looney RJ, Abraham GN, Anderson CL: Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 136:1641, 1986
30. Fleit HB, Wright SD, Unkeless JC: Human neutrophil Fc gamma receptor distribution and structure. Proc Natl Acad Sci USA 79:3275, 1982
31. Zola H, MacArdle PJ, Bradford T, Weedon H, Yasui H, Kurosawa Y: Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol 69:411, 1991
32. Moore K, Cooper SA, Jones DB: Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. J Pathol 152:13, 1987
33. Parham P: On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol 131:2895, 1983
34. Munn DH, McBride M, Cheung NK: Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Res 51:1117, 1991
35. Wallace PK, Palmer LD, Yang JC, Horan PK, Muirhead KA: Mechanisms of adoptive immunotherapy: Improved methods for in vivo tracking of tumor infiltrating lymphocytes and lymphokine activated killer cells. Cancer Res 53:2358, 1993
36. Charak BS, Agah R, Mazumder A: Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: Application in bone marrow transplantation. Blood 81:3474, 1993
37. Baldwin GC, Chung GY, Kaslander C, Esmail T, Reisfeld RA, Golde DW: Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells. Br J Haematol 83:545, 1993
38. Gingrich RD, Dahle CE, Hoskins KF, Senneff MJ: Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood 75:2375, 1990
39. Brochu S, Perreault C, Belanger R: Evaluation of Fc-dependent monocyte-macrophage function in bone marrow transplant recipients. Exp Hematol 17:948, 1989
40. Klingemann HG, Kohn F, Phillips GL: Tumoricidal activity of monocytes after bone marrow transplantation. J Cell Biochem 14A:287, 1990
41. Deramoudt EX, Gilard C, Lepine N, Alonso JM, Romet-Lemonne JL: Bispecific anti-human red blood Rhesus-D antigen x anti Fc gamma RI targeted antibody-dependent cell-mediated cytotoxicity and phagocytosis by mononuclear leucocytes. Clin Exp Immunol 89:310, 1992
42. van de Winkel JGJ, Boonen GJ, Janssen PL, Vlug A, Hogg NT, Tax WJ: Activity of two types of Fc receptors, Fc gamma RI, and Fc gamma RII, in human monocyte cytotoxicity to sensitized erythrocytes. Scand J Immunol 29:23, 1989